Why carry out this study?

Tafamidis is approved in many countries for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

This multicenter, single-arm, post-approval commitment study aimed to evaluate the safety and efficacy of tafamidis in patients with ATTR-CM in China.

What was learned from the study?

The safety of tafamidis in Chinese patients with ATTR-CM was consistent with that previously reported in other international populations with ATTR-CM.

Tafamidis treatment was associated with a stable disease profile over 12 months in a population of patients where most had variant ATTR-CM and mild heart failure symptoms.